Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.50 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 0.50 |
| ▸ | GPR142 | Q7Z601 | 1/20 | 0.48 |
| ▸ | DPP4 | P27487 | 4/20 | 0.48 |
| ▸ | FAP | Q12884 | 2/20 | 0.48 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.48 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.48 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.48 |
| ▸ | CTSC | P53634 | 3/20 | 0.48 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.47 |
| ▸ | TPH1 | P17752 | 1/20 | 0.46 |
| ▸ | CSK | P41240 | 1/20 | 0.44 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9258148 | 1.00 | SAE1 (0.50) | SAE1UBA2GPR142DPP4FAP | |
| SCHEMBL9258141 | 1.00 | SAE1 (0.50) | SAE1UBA2GPR142DPP4FAP | |
| SCHEMBL15307625 | 0.84 | LOXL2 (0.57) | SAE1UBA2GPR142DPP4FAP | |
| SCHEMBL14899604 | 0.83 | DPP4 (0.52) | SAE1UBA2GPR142DPP4FAP | |
| SCHEMBL684432 | 0.83 | DPP4 (0.52) | SAE1UBA2GPR142DPP4FAP | |
| SCHEMBL5569674 | 0.81 | DPP4 (0.48) | SAE1UBA2GPR142DPP4FAP | |
| SCHEMBL16060347 | 0.81 | DPP4 (0.48) | SAE1UBA2GPR142DPP4FAP | |
| SCHEMBL6794672 | 0.81 | SAE1 (0.50) | SAE1UBA2LOXL2TPH1CYP2A6 | |
| SCHEMBL19544842 | 0.81 | SAE1 (0.50) | SAE1UBA2LOXL2CYP2A6 | |
| SCHEMBL14938754 | 0.81 | DPP4 (0.48) | SAE1UBA2GPR142DPP4FAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10654818-B2 | Furane derivatives as inhibitors of ATAD2 | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2020-05-19 | — | — | US | disclosed |
| US-10654818-B2 | Furane derivatives as inhibitors of ATAD2 | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2020-05-19 | — | — | US | disclosed |
| EP-3383865-B1 | FURANE DERIVATIVES AS INHIBITORS OF ATAD2 | Bayer Pharma AG (DE) | 2020-01-29 | — | — | EP | disclosed |
| EP-3383865-B1 | FURANE DERIVATIVES AS INHIBITORS OF ATAD2 | Bayer Pharma AG (DE) | 2020-01-29 | — | — | EP | disclosed |
| US-20190218196-A1 | FURANE DERIVATIVES AS INHIBITORS OF ATAD2 | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-07-18 | — | — | US | disclosed |
| US-20190218196-A1 | FURANE DERIVATIVES AS INHIBITORS OF ATAD2 | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-07-18 | — | — | US | disclosed |
| WO-2017093272-A1 | FURANE DERIVATIVES AS INHIBITORS OF ATAD2 | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190218196-A1 | FURANE DERIVATIVES AS INHIBITORS OF ATAD2 | ATAD2, ATAD2B, TAF1L | SAE1 1113/4885UBA2 1435/4885GPR142 4267/4885 |
| US-10654818-B2 | Furane derivatives as inhibitors of ATAD2 | ATAD2, ATAD2B, TAF1L | SAE1 1113/4885UBA2 1435/4885GPR142 4267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.